Publication | Closed Access

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

Radiation OncologyBreast OncologyHer2-targeted Therapies TrastuzumabPreclinical EvaluationMedicineImmune Checkpoint InhibitorBreast CancerCancer TreatmentSystems BiologyOncologyCell BiologyTumor Microenvironment